✦ LIBER ✦

Differential pricing of drugs: a role for cost-effectiveness analysis?

✍ Scribed by Ruth Lopert; Danielle L Lang; Suzanne R Hill; David A Henry

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biologic drugs for rheumatoid arthritis

✍ Allan J. Wailoo; Nick Bansback; Alan Brennan; Kaleb Michaud; Richard M. Nixon; F 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

PAR10 COST-EFFECTIVENESS AND COST-UTILIT

✍ M Eandi; O Zaniolo; S Iannazzo; L Pradelli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

CO2 ACCOUNTING FOR THE DRUG LIFE CYCLE A

✍ M Hoyle 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Drug policy for visceral leishmaniasis:

✍ V. Vanlerberghe; G. Diap; P. J. Guerin; F. Meheus; S. Gerstl; P. Van der Stuyft; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 503 KB

The role of imaging in Graves’ disease:

✍ C. Cappelli; I. Pirola; E. De Martino; B. Agosti; A. Delbarba; M. Castellano; E. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 93 KB

PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI

✍ F Xie; G Blackhouse; N Assasi; R Hopkins; K Gaebel; D O'Reilly; JE Tarride; RA G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB